Law360 (July 19, 2021, 9:29 p.m. EDT) – A former FDA official said during an opioid trial in California on Monday that it wouldn’t necessarily be a problem if drugmaker Endo’s promotional material included a sentence that regulators had asked to remove from the official label of the product.
Minnie Baylor-Henry, 1995-1999 director of the United States Food and Drug Administration’s Marketing, Advertising, and Communications Division – or DDMAC – spent nearly a day at the stand as a witness expert for Endo, one of the drugmakers defending against claims by four California jurisdictions that they introduced addictive drugs into the healthcare ecosystem and created a …
Stay one step ahead
In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.
Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
Create personalized alerts for specific case articles and topics and more!